Eye drop holds promise to halt diabetic blindness
NCT ID NCT04505566
Summary
This study aims to understand how inflammation contributes to diabetic retinopathy, a leading cause of blindness. Researchers will measure specific inflammation markers in the eye fluid of 164 adults with type 2 diabetes. A portion of participants will also test if daily use of a ketorolac eye drop can reduce these markers and potentially slow the progression of the eye disease over one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.